MackG... agree in part...

Agree...

But...I believe we will get initial results on Brilacidin's efficacy ...before end of year...therefore BEFORE Jan 1st.

Here Today...spot on again!

(and post/er to which you responded is once again...incorrect)

RESPONSE: ABSOLUTELY! As part of the application for IND, the Sponsor (IPIX) MUST submit the prospective sites for testing! So, OF COURSE, LEO knows where he CAN GO for CT...which ones finally choses, out of that list, is up to IPIX.



RESPONSE.. NO, it would be a first "NOT TO HAVE" those sites already cased out and available for CT! In fact the Pre-IND would be rejected without those sites noted!

The only information needed so that the SPONSOR COULD MOVE "on a dime's notice" would be the "Protocol" set out by the FDA...once received (before final award of IND) ... IPIX could set up "overseas" Protocol to conform with FDA...BEFORE IND APPROVAL...

Conclusion...IPIX could have "foreign sites" set up with FDA protocal and "be ready on a dime" to commence trials...especially if the country in question is bombarded with hospitalized cases where Patients would immediately conform to protocol...

HERE TODAY... YOU ACCURATELY STATE:






FOR THOSE CONCERNED...that the "overseas" approval will be questioned because the CT were held in Foreign country like perhaps...RUSSIA

...as noted above...THESE CT ARE RUN BY U.S. CROs who are going to report results to the FDA! (and submitted and used to Foreign regulatory body for approval)

...that LEO guy...the CEO? Clever AND Smart!

...do yours own DD, draw your own conclusions regarding negative posts on Leo and KNOW WHAT YOU OWN!

PS...for all you who would hope we get to .14 and will sell...I'm up for them... to add to my 2.5M

Rdunn...YOUR RECENT ERRONIOUS POSTS: (corrected)

YOUR POST #1.   

...statement: "Leo's Sunday alert destroyed the stock.....for releasing DUPLICATE (EXCELLENT) NEWS..."
 
RESPONSE:   A total "non-affect"...Sunday's alert was a FULL TEXT of abbreviated SUMMARY which the company initially released...
"Destroyed the Stock"...more like disseminating the GOOD NEWS...Your statement is a "fabrication" of an issue.  Disseminating GOOD NEWS again and more completely is a GOOD THING ... Your statement and inference is a NON-ISSUE.

statement:    referring to a "GRANT FILING ERROR"

RESPONSE: ...there was NO ERROR IN THE GRANT...Grant was filed in anticipation RBL would  adhere to its timeframe for completion of Human Tissue Test Results...the delay cause by the RBL/GMU mishaps in the lab regarding short personnel and not meeting its own deadlines is far from a LEO problem.  Submitting grant application to meet a deadline for submission, with the right to supplement and amend up to a certain date ...IS NOT AN ERROR.   SUBMITTING AND SUPPLEMENTING up to a final deadline one expects to meet (relying on GMU) is good and indicates proactive and aggressive management.  Would you prefer LEO not make an application for a grant...because he is waiting for a piece, then gets the piece but cannot submit because it never intially filed full package for consideration?


YOUR POST #2: 

RESPONSE:: FIRST...ASPIRE FINANCE ANY PORTION OF THE $30M IPIX has the right to PUT to them, unless IPIX requires them to do so (PUTTING IT TO THEM)there is NO SALE OF STOCK !   All stock which IPIX "PUTS" to ASPIRE...they are REQUIRED TO BUY (at a discount).   SINCE THEY ARE FINANCIERS (not investors) they are expected to sell back to the market immediately at a higher price for their "profit".   (
(THIS IS EXACTLY WHAT FLIPPERS ON THIS BOARD DO WHO SELL INTO THE BID OR SUBMIT SIZE AT THE ASK....AFTER they sell...they then talk down the stock on the board to buy back lower from "scared" longs.)

 ASPIRE is a financer...the DONT HOLD ANY STOCK...they lend money...how they and all financiers operate...is not a reflection of the fundamentals. They are professional flippers...like the non-professional those who operate here.

YOUR POST # 3. 


RESPONSE:VACCINES are not THERAPEUTICS....Brilacidin is a THERAPEUTIC...the dire need to KILL the virus with a Therapeutic...once contracted... is in GREAT NEED....making Brilacidin far from "irrelevant'....(very obvious)
 
BUY! BUY! Buy!...Christmas in Moscow (FYI "WSBC" I prefer St. Petersbrug more)  )

williamssc...you are absolutely correct... (Rdunn, incorrect)

If wanted...likely they can produce 100 Million doses (less complicated to formulate) at a fraction of the cost of, and likely infinitely more effective than Remdesivir


Upon first positive CT POC indications, under the Defense Procurement Act: "The federal government can, ...use it to jump ahead of other clients or issue loans so a company can buy all of the supplies it needs to complete the government’s order by a specific date. A rarely used authority of the law also allows the administration to control the distribution of a company’s products and determine where such materials go."

BINGO! J&J and PFE are drug production monsters in U.S. and can be ordered to produce Brilacidin before anything else..."...the Defense Production Act has been used to place hundreds of thousands of orders by President Trump and his administration to ensure the procurement of vital equipment..."


Where will "Overseas" Trials be conducted?

Look at the dynamics and who is likely engaged in IPIX's decision where CT should occur...

Regarding prior CT of Brilacidin, before IPIX's technology purchase, Dr DeGrado (now Scientific Advisor to IPIX), who is a member of the National Academy of Science, the National Academy of Inventors, the American Academy of Arts and Sciences, and a fellow of the American Association for the Advancement of Science, ... a past President of the Protein Society and was the scientific founder of PolyMedix, which discovered brilacidin...also served as President, Chief Executive Officer and Director of PolyMedix, Inc.

Where did PolyMedix conduct Brilacidin Clinical Trials for "successful" ABSSSI indication? RUSSIA Federation...11 sites in Russia and 5 sites in Ukraine

Brilacidin ... ABSSSI Human Clinical Trials...

Sponsors and Collaborators
PolyMedix, Inc. (IP developer from whom IPIX acquired Brilacidin).


Locations
Canada, Ontario
Hamilton, Ontario, Canada, L8N 4A6
Canada, Quebec
Chicoutimi, Quebec, Canada, G7H 5H6
Greenfield Park, Quebec, Canada, J4V 2H1
Sherbrooke, Quebec, Canada, J1H 5N4
Trois-Rivieres, Quebec, Canada, G8Z 3R9
Canada
Quebec, Canada, G1V 4X7
Russian Federation
11 Sites
Multiple, Russian Federation
Ukraine
5 Sites
Multiple, Ukraine
Sponsors and Collaborators
PolyMedix, Inc. ...

With the highly charged partisan politics of in FDA of not wanting to give Trump any positive news...IMO conducting Brilacidin CT in Russia would be a brilliant decision by Leo and DeGrado...less bureaucratic, with "warp speed" like turnaround possible...

IMO we should be looking for CT to start in Russia by first week in Dec...(if not before)...informal indications within 7 days thereafter...definitive results reported by Certifying 3rd parties (Outside Russia and in U.S. or E.U.) within 30 days thereafter...



.

Familyman stated: "...mind-blowingly crucial data because it became available one week too late?!?! Unbelievable!!!"

Welcome to "The Bureaucracy"...contrary to KFCyahoo's response implying Leo controlled the RBL reporting results to IPIX (which he did and does not) and the deadline for the rolling grant review passed.  But fret NOT...the grant application roles over to the next period and deadline...so my understanding is that the data information (and more) is in the next grant period for review. 

Blaming Leo for RBL delays in assembling and releasing data which IPIX has/had no control over is a non-starter...pure BS.   Of course, you won't hear from the same critic(s) throwing accolades in Leo's direction for submitting applications for Brilacidin's regulatory approval in two jurisdictions (U.S. and "Overseas").
  
Regarding IND...PR clearly states IPIX was complying with minor comments made by FDA re: IND application ...so IMO the answer is clearly YES: "...IPIX has been packaged the trial format the way FDA wants it."...and now we wait the 30 days. ... meanwhile IPIX has application in "overseas" jurisdiction for Human Clinical Trials for  drug approval in that jurisdiction, which CT results will also be used in the U.S.

In the end..with Leo's strategy...IF INTENTIONAL DELAY...by FDA...after stellar results in Trials in U.S. and Russia and Russia's approval...FDA will have serious egg on its face and support a huge FOX New and FOX Business News campaign. 

Meanwhile on the vaccine front PFE and Moderna are locked in "ONE UP ON YOU" trying to push the envelope on representations of efficacy....but SAFETY is far from settled. 

IMO...discussion about AlfaSigma is a non-starter...because they are a non-starter with Brilacidin and likely default in its licensing agreement and return it back all of its rights under their limited licensed B-UP...good for IPIX.

With successful "overseas" trials and emergency approval...even without U.S. regulatory movement...YES, Kingofsting...IPIX can hit $5.00 by March. 

Expecting IPIX to commence launch of Clinical Human Trials in Eastern Europe ...by end of November or first week in December with feedback on preliminary results very quickly...

wsbc cites Russia as the "Overseas" country and with IPIX (predecessor - B- Absssi trials)having past trials there, I would strongly concur...

If Russia, I would not be surprised we get "approval" shortly after 90(+) (-) patient trial is completed. The $ to be made is not the important factor...It prompts regulatory agencies from other countries to review and look seriously at Brilacidin for regulatory review and approval (including FDA).

Russia likely chosen for being both more responsive (if Putin wants it Putin gets it) and a quicker regulatory review /approval process and much less expensive than U.S. trials. (if the Hospitals charge at all...since they are in such a crises)

As per PR...balance of Clinical trials will be in U.S for seeking FDA approval

Rdunn88 you stated this AM:

Wrong again...PR states Clinical Human Trials "overseas" in 2020...likely end of month OR 1st week Dec...IMO...watch for equivalent of EUA in foreign countries in Q4 ...all within 2 months! 

Only thing that is "toast" is your prediction. 

 


PR evidenced efficacy vs. second Sars-2...indicating Brilacidin likely protect against MUTATED VIRUS....how much is that worth as virus Mutates. Brilacidin's science is compelling and confirmed by RBL...now expanded to cover mutations. Very Compelling, Very Valuable...


olden_grumpini  

The successful execution of the SCIENCE is worth many multiples of cost of dilution.

Smart of Leo not disclosing "Overseas" clinical Trials . There are too many jerks who in the past has disrupted Clinical Human Trials of other indications... NEWS OF RESULTS is all we need to know and keep our eyes on. 

Here Today...

...correct...Leo shows his cleverness by going for FDA and Overseas approval using same 120 patient trial (combined of the two countries)... 


IMO...wsbc...signaled the country where "Oversea's" clinical trials will 
be approved and commence by eom.  Read his posts.  The country is raveged with Covid and had a failed Vaccine. 

Also...my guess is that the Oversea's country's Human Trials will be paid for by the country (or look for minimal $ from IPIX)...good chance IPIX not pay for anything other than supplying Brilacidin...againONLY a guess...   

LOL...

you state:

Big boys wrapping up a Win?... They are playing soccor, (vaccine), we are playing baseball (therapeutic)...To what THERAPEUTIC WIN are you referring?

PFE ... producing a Vaccine...Win? to be determined!...but its not playing or on IPIX's field.

GILD...a feeble, limping Therapeutic (Remdesivir)...hardly a WIN!... more like an ON FIRST ("on first, hit by a pitch"th rown by Fauci...intentionally)

So no "effective win" on the Therapeutic field...the game Brilacidin is playing in.

How does B get shipped?...try Overnight and Prepped (constituted) at Hospital where dispensed...no unrealistic temperature control during shipping...

Who is paying for manufacturing...with expected Successful Trials...Barda, DOD, NIH...many agencies throwing $ at it.

It's moot point...

sunspotter is wrong...Operation Warp Speed also lessoned FDA time period for vaccine review and development

Sent to Rudy Giuliani and John McLaughlin

tiab...LAUGHABLE!

According to you there was no progess with the writing of the Pre-Print PEER REVIEW ARTICLE...and

... intimated that nothing good would be coming...then suddenly dramatic confirmation of all Brilacidin's attributes!

... You are aware that FDA does not communicate the "progress" of their review of IND applications...therefore, AS WITH PEER REVIEW ARTILCE. you are assuming "no progess" which conclusion is void of rational thought...which will result in the same consequenses...GREAT NEWS COMING!

Human Trials will commence this quarter.

GREATG NEWS...From the George Mason University RBL - Pre-Print PEER REVIEW ARTICLE:
(from other poster)

“Clearly, an effective COVID-19 therapeutic (or therapeutics in combination) ideally would control both viral load and the corresponding inflammatory damage due to SARS-CoV-2,93 and mitigate bacterial co-infections. Exhibiting three-in-one properties—antiviral, immuno/anti-inflammatory, and antibacterial—brilacidin is being developed for the intravenous treatment of COVID-19 in hospitalized patients and may be able to address different disease parameters within the one therapeutic treatment.”


“Interestingly, the inhibitory potential of brilacidin was best observed at the highest MOIs tested, with inhibition of virus at the lower MOIs (0.01 and 0.001) not showing statistical significance (Figure 3C). The inhibition exerted at the MOIs of 0.1 and 0.05 were extremely comparable to each other.”


“Our experiments in the Vero cell line model demonstrate brilacidin decreases viral load in a robust manner when the virus is pre-incubated with brilacidin (Figure 2D), suggesting brilacidin impacts the virus directly.”


“These findings indicate brilacidin causes significant cell wall stress and additional internal stress due to the accumulation of misfolded proteins. Additional mechanistic studies of brilacidin analogs against Escherichia coli, in comparison to the antibiotic polymyxin B, further support this class of compounds ability to destabilize bacterial membranes.”


“Remdesivir and favipiravir are inhibitors that impact the viral RNA synthesis step of the infectious process. These drugs may help decrease progeny viral genomes in infected cells, but they will not be conducive to inhibiting progressive infection of naïve cells once the progeny virions have been released from infected cells.”

“Furthermore, remdesivir and favipiravir do not possess intrinsic anti-inflammatory activity, unlike brilacidin.”


“Consequently, use of a drug strategy that exhibits intrinsic anti-inflammatory activity will add value to controlling later onset inflammatory damage in COVID-19 patients, potentially occurring beyond the time of active viral multiplication.”


“Experiments conducted in endemic human coronaviruses are ongoing, with additional testing planned in other lethal coronaviruses (MERS-CoV, SARS-CoV), toward assessing the potential of brilacidin as a broad spectrum inhibitor of coronaviruses.”

You state:

Correct... but that's too simple and limited statement

While Brilacidin requires Human Trials as an FDA approved therapeutic for Covid-19...

Not all of the Phase II (which it would be in) Human Trials for the FDA are necessary and required to occur in the U.S.

In fact, IPIX could conduct those Phase II Human Trials in another regulatory "friendly" country, and receive that foreign country's "regulatory approval" as approved therapeutic in that country...demonstrating efficacy against Covid-19 to countries.

...all of which could occur before, or simultaneously while going through and seeking FDA approval via Human Trials.


...interesting scenario? far fetched?... IMO...yes, it is interesting but not far fetched and likely to happen, if deep state plays with (delays) IND approval.

As per PR...Look for 4th Quarter Human Trials... the question is which starts first U.S trial sites or overseas sites? (Rhetorical question...no need to respond!)

p.s. "there is more than one way to skin a (political) cat!"

YOU QUESTION: "How is the (longs) TRUST LEVEL SO HIGH...?"

EASY ANSWER: SUCCESS and POSITIVE FACTS DO NOT LIE.!!!

Below...ALL FACTS!

October 2, 2020

INNOVATION PHARMACEUTICALS ANNOUNCES PRE-IND MEETING REQUEST GRANTED BY FDA FOR THE STUDY OF BRILACIDIN FOR THE TREATMENT OF COVID-19

September 15, 2020

LABORATORY TESTING OF BRILACIDIN FOR COVID-19 IN COMBINATION WITH REMDESIVIR REDUCES VIRAL LOAD BY NEARLY 100 PERCENT

August 26, 2020DR.

WILLIAM F. DEGRADO, A DISCOVERER OF BRILACIDIN, JOINS INNOVATION PHARMACEUTICALS AS SCIENTIFIC ADVISOR

August 24, 2020

COVID-19 DRUG CANDIDATE BRILACIDIN ACHIEVES A SELECTIVITY INDEX AMONG THE HIGHEST REPORTED, EXHIBITING POTENT ANTI-SARS-COV-2 ACTIVITY AT LOW CONCENTRATIONS; CLINICAL TRIAL FORTHCOMING

August 4, 2020

INNOVATION PHARMACEUTICALS AND U.S. REGIONAL BIOCONTAINMENT LABORATORY NEARING COMPLETION OF BRILACIDIN ANTI-SARS-COV-2 (COVID-19) IN VITRO TESTING

July 20, 2020

INNOVATION PHARMACEUTICALS’ BRILACIDIN INHIBITS NOVEL CORONAVIRUS (COVID-19) BY ALMOST 90% AT THE LOWEST CONCENTRATION TESTED TO DATE IN A HUMAN LUNG CELL LINE

July 13, 2020

INNOVATION PHARMACEUTICALS – CLINICAL TRIAL TESTING OF BRILACIDIN AGAINST SARS-COV-2 (COVID-19) TARGETED TO COMMENCE Q4 2020

July 7, 2020

IN VITRO TESTING OF INNOVATION PHARMACEUTICALS’ BRILACIDIN FOR COVID-19 SHOWS CONSISTENT ANTI-SARS-COV-2 EFFICACY; MANUFACTURING PREPARATION UNDERWAY FOR COVID-19 CLINICAL TRIAL

June 17, 2020

INNOVATION PHARMACEUTICALS’ BRILACIDIN INHIBITS SARS-COV-2 (COVID-19) BY 97 PERCENT IN A HUMAN LUNG CELL LINE

June 11, 2020

INNOVATION PHARMACEUTICALS COLLABORATING WITH REGIONAL BIOCONTAINMENT LAB ON GRANT APPLICATION TO RESEARCH BRILACIDIN AS A PAN-CORONAVIRUS THERAPEUTIC

May 26, 2020

INNOVATION PHARMACEUTICALS RECEIVES DATA FROM PUBLIC HEALTH RESEARCH INSTITUTE SHOWING BRILACIDIN INHIBITS SARS-COV-2 (COVID-19) IN A HUMAN CELL LINE

May 19, 2020

INNOVATION PHARMACEUTICALS’ BRILACIDIN REDUCES VIRAL TITER OF SARS-COV-2 (COVID-19) BY 75 PERCENT AFTER ONLY 1 HOUR OF PREINCUBATION IN IN VITRO STUDY AT BSL-3 FACILITY

May 5, 2020

INHIBITORY EFFECT OF INNOVATION PHARMACEUTICALS’ BRILACIDIN ON SARS-COV-2 (COVID-19) IN PRIMARY HUMAN IMMUNE CELLS TO BE STUDIED AT LEADING PUBLIC HEALTH RESEARCH INSTITUTE

April 27, 2020

INNOVATION PHARMACEUTICALS INFORMED NEXT PHASE OF BRILACIDIN CORONAVIRUS (COVID-19) TESTING TO BEGIN WEEK OF MAY 4

April 6, 2020

INNOVATION PHARMACEUTICALS IN DISCUSSIONS TO ADVANCE BRILACIDIN INTO HUMAN TRIALS AGAINST COVID-19

April 1, 2020

INNOVATION PHARMACEUTICALS RECEIVES DATA SUPPORTING BRILACIDIN’S DIRECT INHIBITION OF SARS-COV-2, THE NOVEL CORONAVIRUS RESPONSIBLE FOR COVID-19

March 17, 2020

INNOVATION PHARMACEUTICALS BRILACIDIN TO BE RESEARCHED AS POSSIBLE NOVEL CORONAVIRUS (COVID-19) VACCINE; BRILACIDIN NOW BEING TESTED AS DRUG AND VACCINE AT DIFFERENT INSTITUTIONS

Finally, how long once we get IND approval will it take to get the human trial going? Hospitals and protocol imo set up...but protocol would be changed if IND requires tweaking...a matter of days to modify protocol.

"DeGrado doesn't win the Nobel Prize"... I emailed Wm DeG the same...said I expect him on stage in Stockholm...in 2021. His email response came with a blush.

Coincidently the 2020 winners were for the discovery of Hep C Virus...wouldn't it be appropriate if Brilacidin could kill the Hep C Virus!!!

https://www.nobelprize.org/prizes/medicine/2020/advanced-information/
The 2020 Nobel Prize in Physiology or Medicine is awarded to Harvey J. Alter, Michael Houghton and Charles M. Rice for the discovery of Hepatitis C virus. Hepatitis, from the Greek names for liver and inflammation, is a disease characterized by poor appetite, vomiting , fatigue and jaundice - yellow discoloration of the skin and eyes .

LOL...worried that "Glowing" data and results of tests which will be in the Pre-Print of Peer Review Article from GMU scientists will turn heads?

IMO...you should be. Its time for Pre-Print...and IMO within the week we a "glowing" Pre-Print will be out.... Also for the public/public it will further supplement to and support for IND application submitted, though not necessary, since data would have been in the IND.

It is also good insurance that the "political" FDA cannot and will not bury Brilacidin and its results.

As noted, TRUMP card in Pre-Print Peer Review will be any discussion about tests involving Brilacidin with Remdesivir...IMO it can't and won't be ignored.

Political ... imo "save face" for Fauci's manipulation. Brilacidin will blow it away...as IMO will be demonstrated in the GMU Pre-Print Peer Review article.

imo...the pre-print from GMU is likley finished and submitted to company for review...I would expect, if I am correct, release sometime this week... real wildcard is what has been discussed in article about combo Remdesivir/Brilacidin and data demonstrating the workhorse is Brilacidin.

STRAWMAN/KNOCKDOWN ALERT!

IN RESPONSE TO POST REGARDING IND application etc...

The post sets up Strawmen and Knockdowns by asking the following questions (and makes assertion):

1. "Who is completing the Peer Report (final data)? Believe 2 RBL's were involved or possibly 3... GMU came on-board in late May and we don't know who were involved in March..."

STRAWMAN: Question sets up falsehood that company did not inform us:
KNOCKDOWN: "OMG COMPANY DID NOT TELL US AND WE DONT KNOW WHO IS INVOLVED!"..."OMG! UNCERTAINTY...WILL IT EVER HAPPEN?"

FACT: Leo clearly informed us via June 11th PR (in part below)...that two separate entities informed the company that they would be publishing 2 separate Peer Review Article on their respective findings.

NOTE: They are not going to waste their time unless there is new and fantastic findings the scientific world did not know about Brilacidin.

PR-6/11/2020 "...The ongoing Brilacidin anti-SARS-CoV-2 research being conducted at the RBL is separate from the ongoing research being performed at a Public Health Research Institute (PHRI). The lead researchers at both the RBL and at the PHRI have informed the Company they plan to submit their findings, separately, upon completion of in vitro testing, for peer-review publication.  

2. "I'm assuming they'll need data from all parties for the FDA?" 

STRAWMAN: "IND Submission can not take place if any RBL is still conducting even optional testing.
KNOCKDOWN: "LEO reported in PR below that GMU still doing testing...therefore Pre-IND Review and Acceptance has not and cannot take place.

FACT: PR's below indicate all the testing and that GMU RBL completed its task by end of September. Additional test were optional and at the expense and interest in Brilacidin by GMU scientist...who already commenced writing her Peer Review Article. Additional testing could supplement article within 60 days of pre-Peer Review publication.

PS...IMO...the Rutgers's Public Health Research Institute (PHRI) article is likely due out any day, since it was not doing additional testing.  

List of PR's related to testing...read each one for the above info.
 
October 2, 2020INNOVATION PHARMACEUTICALS ANNOUNCES PRE-IND MEETING REQUEST GRANTED BY FDA FOR THE STUDY OF BRILACIDIN FOR THE TREATMENT OF COVID-19

September 15, 2020
LABORATORY TESTING OF BRILACIDIN FOR COVID-19 IN COMBINATION WITH REMDESIVIR REDUCES VIRAL LOAD BY NEARLY 100 PERCENT

August 24, 2020COVID-19 DRUG CANDIDATE BRILACIDIN ACHIEVES A SELECTIVITY INDEX AMONG THE HIGHEST REPORTED, EXHIBITING POTENT ANTI-SARS-COV-2 ACTIVITY AT LOW CONCENTRATIONS; CLINICAL TRIAL FORTHCOMING

August 4, 2020
INNOVATION PHARMACEUTICALS AND U.S. REGIONAL BIOCONTAINMENT LABORATORY NEARING COMPLETION OF BRILACIDIN ANTI-SARS-COV-2 (COVID-19) IN VITRO TESTING

July 20, 2020
INNOVATION PHARMACEUTICALS’ BRILACIDIN INHIBITS NOVEL CORONAVIRUS (COVID-19) BY ALMOST 90% AT THE LOWEST CONCENTRATION TESTED TO DATE IN A HUMAN LUNG CELL LINE

July 13, 2020
INNOVATION PHARMACEUTICALS – CLINICAL TRIAL TESTING OF BRILACIDIN AGAINST SARS-COV-2 (COVID-19) TARGETED TO COMMENCE Q4 2020

July 7, 2020
IN VITRO TESTING OF INNOVATION PHARMACEUTICALS’ BRILACIDIN FOR COVID-19 SHOWS CONSISTENT ANTI-SARS-COV-2 EFFICACY; MANUFACTURING PREPARATION UNDERWAY FOR COVID-19 CLINICAL TRIAL

June 17, 2020
INNOVATION PHARMACEUTICALS’ BRILACIDIN INHIBITS SARS-COV-2 (COVID-19) BY 97 PERCENT IN A HUMAN LUNG CELL LINE

May 26, 2020
INNOVATION PHARMACEUTICALS RECEIVES DATA FROM PUBLIC HEALTH RESEARCH INSTITUTE SHOWING BRILACIDIN INHIBITS SARS-COV-2 (COVID-19) IN A HUMAN CELL LINE

May 19, 2020
INNOVATION PHARMACEUTICALS’ BRILACIDIN REDUCES VIRAL TITER OF SARS-COV-2 (COVID-19) BY 75 PERCENT AFTER ONLY 1 HOUR OF PREINCUBATION IN IN VITRO STUDY AT BSL-3 FACILITY

May 5, 2020
INHIBITORY EFFECT OF INNOVATION PHARMACEUTICALS’ BRILACIDIN ON SARS-COV-2 (COVID-19) IN PRIMARY HUMAN IMMUNE CELLS TO BE STUDIED AT LEADING PUBLIC HEALTH RESEARCH INSTITUTE

3. "This thing could drag on for months..."

STRAWMAN: "WE WERE TOLD THE DATE OF PUBLICATION OF PEER REVIEW AND IT PASSED!"
KNOCKDOWN: WE PASSED A (FICTIOUS ) DEADLINE "I" WANTED...THEREFORE IT WILL NEVER HAPPEN!"

FACT: Company has no control over when an independent US Affiliate Agency will or does anything...especially a voluntary PEER REVIEW ARTICLE. We do know original Testing was to end September 30th.

4. "The revenue potential for B keeps dropping as time passes on..."

STRAWMAN: "VALUE OF BRILACIDIN IS DECAY ING OVER TIME!" 
KNOCKDOWN: "ALL THESE FANTASTIC (and fictious) NEW THERAPIES HAVE COME ON THE MARKET...AND AS MORE REMDESIVIR-LIKE BLOCKBUSTERS THERAPIES COME ON THE MARKET...BRILACIDIN HAS EXPOTENTIALLY DEPRECIATED!"

FACT: NO THERAPY CLOSE TO THE POTENTIAL OF BRILACIDIN HAS BEEN APPROVED AND REMDESIVIR HAS (AS REPORTED) IS AN ABJECT FAILURE IN EFFICACY TO STEM THE VIRUS AND MORTALITY... WE REMAIN THE POTENTIAL THERAPY WITH THE MOST EFFICACY POTENTIAL!

IN FACT BRILACIDIN IMO...BECOMES MORE VALUABLE OVER TIME...as all other Therapies are failing.

(PS. To poster "LIVED" Gilead needs Brilacidin like oxygen...Remdesivir an abject failure! Brilacidin alone achieves 97% viral load reduction...add Remdesivir and total load reduction = 99.85% meaning REMDESIVIR accounts for only 2.85% viral load reduction = garbage.)

IN RESPONSE TO POST cited below, it is important to discern the difference between "fact" and drawing "false conclusion" based upon "false premises" or "false assumptions"

Every investor must be discerning about Posts using an event or non-event as "facts" and setting up "strawman" to "knockdown" thereby creating false conclusions and/or doubt, attributable to that "fact" used knockdown and create appearances of IPIX failure. 

What are the the real facts here?

1.  "Can the company go another day without news?"

STRAWMAN..."NEWS WAS DUE" 
KNOCKDOWN...THE COMPANY HAS NEWS OR SHOULD HAVE NEWS TO REPORT AND ISN'T"...there is a Problem!" 

No news? SO WHAT!...would investors like "fake" or "fluff"  news to satisfy impatience?  News comes out when there are new events which  in management's view, support the material progress or failure of company's progress...ie  "news"...eg pre-print peer review articles, more optional RBL Brilacidin test results, IND designation by FDA , grant funding, test site designation and selections, etc. etc. etc. 

 
2.  "At some point it begins to feel like there is a real problem instead of a real huge bonus surprise." 
 
STRAWMAN..."IND and/or PEER REVEIW ARTICLES ARE OVERDUE!"
KNOCKDOWN..."THERE IS A PROBLEM"..."THE FDA IND APPROVAL AND PEER REVIEW WERE DUE AND HAVE NOT BEEN ISSUED, THEREFORE  READER SHOULD PRESUME THERE IS A PROBLEM WITH IND DESIGNATION AND THE PEER REVIEW IS GOING TO BE  NEGATIVE" 
 
Post implies FDA response to IND application and/or  Peer Review Articles  are overdue.  Waiting for FDA bureaucracy to respond.  There is no basis for "feeling" that there is a problem.  Poster making up his own deadlines...Why should we expect NEWS BEFORE FDA is required to report? (60 days from submission...we are 20 days out...but IMO we will receive 1st week of Nov.) Response to IND approval is not in the control of IPIX.


3.  "Why no data?"

STRAWMAN: Data is required to be released by Company or RBL as soon as it is available. 
KNOCKDOWN:  No Data = Data is not good or there is a problem with it. 

Post ignores that RBL owns the data and dictates when it can be released.  Since RBL is writing a Peer Review article on the successes of Brilacidin, as a matter of course, DATA is not released until the pre-print Peer Review article is released.  The Data will be explained by originator of that data, i.e. RBL and not left to wild assumptions by those who are ignorant to the process.  There is no negative assumption to be made by non-release...simply SOP for researcher who is writing an article based upon the data.
 
4.  "If we cannot see data how will they persuade the FDA?"

STRAWMAN: FDA did not receive the Data in IND application.
KNOCKDOWN: FDA will not be persuaded and will reject IND
application. 

5.  "Weird that they have nothing to say."

STRAWMAN: FDA and/or RBL were due to report something.
KNOCKDOWN: FDA and/or RBL failure to report something = Failure.

False implication again as explained above!

Loanranger... you repeat and state:

...then go on to state:



"Bingo"?

"Neither of those are foregone conclusions, are they?"

I applaud you for having an uncanny grasp of the obvious!

When is anything a guarantee...before it happens? Investment decisions in Biotech development companies are made on Scientific probability of success in proving hypothesis and in this case of how and why Brilacidin will be a Covid-19 killer. That high probability of success is based upon DeGrado's development and scientific papers, which were supported by successful Human Trials for other indications, and the strong RBL test results yielding strong empirical evidence (test results) that Brilacidin could have a strong probability of destroying Covid-19.

...to whom? Average investor? likely...but so what? It is the scientific community (PhD's and MD's) and regulatory authorities (FDA, BARDA, NIH, etc.) who count and will understand immediately. Guarantee you that "plain language" will be used by the company and other reporting vehicles to explain the significance of Brilacidin.



Of course not!...they cannot until the IND has been granted...which is what we are waiting for...

As noted before...OWS has been a tremendous success...every firm who's name could be associated with biotech has been submitting (at virtually no cost) Pre-apps for IND, gumming up the "warp" speed. It was normally 60 days, upon the "operation" announcement went down to 5 days...but now is at 30 days...

IMO...we are days away from receiving designation, at which time the Trial Sites lined up can receive IV Brilacidin for administering pursuant to protocol approved.

to "the trial hasn't been scheduled yet"...I say...so what! They can't be until IND granted.

IMO...Peer Review articles are already being written...completion does not depend upon these additional tests conducted by RBL through already existing Grants received unrelated to IPIX (yes... more free testing)...Pre-Printed Peer Review articles from both test sites can be and IMO will completed even while other tests are conducted, and COULD be before IND designation granted...meaning at ANY time. Before final draft submitted for publication, they can be amended, I believe up to two times...within time period.



IMO...Small and controlled sites will start recruit and administer immediately...(plenty of patient pools in U.S. and abroad) thereafter (within a week) imo again... fireworks will begin with leak of success of these smaller trial sites in days of administration of the IV.

IND approval first required...likely Nov. 4th...no coincidence

Dr. Debones...you stated:

Exactly WHAT DATA was Dr. Agus PRIVY TOO?...the answer is NONE.
TIAB has been crying for data behind the RBL results...and he has found none...one of his biggest complaints...

BUT THE FACT IS there has not been a release of data from the RBL tests...the only information released and to be released before the Pre-print PEER review articles were those data points revealed to the company by the RBLs and stated in the PRs.

So when he says "no convincing data" he is not saying the data is bad...he can only means there is no data from which he can draw a conclusion....ONE WAY OR THE OTHER!

...and we all knew that! Wait for the Pre-Print ... then ask the same question...likely a much different response!

While no doubt...every age category could likely experience cases reaching mortality...

This link provided the most startling statistic that 42% of covid-19 deaths occurred in Nursing Homes and Assist. Living Facilities. (and that number did not reflect those transferred and died in hospitals). But it did reflect the mishandling of the crises by State Governors...who took their direction by listening to King Fauci and Co issuing guidelines (which changed almost every day in an ambiguous and contradicting way).

https://freopp.org/the-covid-19-nursing-home-crisis-by-the-numbers-3a47433c3f70

Some, like Cuomo, followed their own misguided paths...to exacerbate the problem with "non"-caring for the elderly living in these restricted facilities by mandating (executive order)them to take covid-19 elderly even though they could not safely do so...

https://khn.org/news/is-cuomo-directive-to-blame-for-nursing-home-covid-deaths-as-us-official-claims/

The interesting thing about the current spike in states that previously had very low covid-19 infection is that now they are exploding...and people are surprised...

Didn't it dawn on the experts that eventually, with a highly infectious disease...and highly mobile country, that everyone...with the exception of those "imprisoned" in their carefully restricted Nursing/Assisted living Facilities are likely going to be exposed?

It only takes one mobile infected person in this country to become a super-spreader...physical prophylactic's (masks and hand washing)...will never be 100% bullet proof.

IMHO...The only way to end the scenario/cycle is to develop and dispense a highly effective therapeutic to kill the virus upon contraction.

...has anyone here ever heard of Brilacidin?

(that's my one post for the day...and I can't respond if you comment on it)

Peter...also Regeneron-EI Lily antibody cocktail would likely be ineffective if the virus mutates to any meaningful degree. Remdesivir (without Brilacidin) is marginally effective.

Meanwhile Dr. Brian Garibaldi of Director, Johns Hopkins Biocontainment Unit, Associate Professor of Medicine and who is DJT's personal pulmonologist, and who treated and is treating him during this contraction of Covid-19...is being introduced to Brilacidin today. and IMO...he will get it immediately!

What he does with his new knowledge is anyone's guess...but when one reads "Remdesivir + Brilacidin" = 100% Covid-19 viral load reduction...it begs the next very serious investigative step.

Mutations will not reduce Brilacidin's effectiveness...since laboratory evidence has demonstrated it "pops and destroys" ANY "envelope shelled" virus...which is the structure of what Covid-19 and most other viruses are.

https://www.hopkinsmedicine.org/profiles/results/directory/profile/0018509/brian-garibaldi


https://www.msn.com/en-us/news/politics/johns-hopkins-doctor-among-those-assisting-with-covid-19-treatment-plan-for-president-trump/ar-BB19FT6P

ps...Peter...please look at your PM

KarinCA...you got it almost right...as I misspelled in the original post...the restaurant which hosted Minority Leader Kevin McCarthy for the Andrew Garbarino Congressional Fundraiser, on Sunday evening ... it was Verace at 599 Main St. Islip, NY 631-277-3800

As several have noted, when calling the restaurant you can only leave a message on the answering machine...and they will call back callers, assuming its restaurant related (and not Posters bothering them).

An easier way to possibly verify Congressman Kevin McCarthy's attendance and transmission of information referenced in the prior email...by emailing the staff member who accompanied the Minority Leader...which I will send you under PM. (he doesn't need to be harrassed by posters)

ps. KarinCA...food was delicious.

It occurred this evening...with a group of 25...dining with Congressman Kevin McCarthy at his table, in a restaurant (Vesca) located in Islip, NY.

Discussed and Noted: DJT was administered Remdesivir, and that a Brilacidin/Remdesivir combination testing at RBL produced an almost 100% covid-19 viral load reduction...

McCarthy..."impressive"

It was followed up with McCarthy receiving an EMAIL with the content below (and more), as well as contact info for appropriate parties:

Summary Highlights

BRILACIDIN RBL Results...outstanding: Brilacidin, manufactured by Innovation Pharmaceuticals, Inc., has gone through 3 very successful "independent" Regional Biocontainment Laboratory Tests (George Mason University) demonstrating UP to 97% Covid-19 Viral Load Reduction when tested using Human Lung, Kidney and Liver tissues, thereby making it potentially the top efficacious Covid-19 prospective therapeutic to kill and destroy the viral cell in the human body. http://www.ipharminc.com/press-release/2020/6/17/innovation-pharmaceuticals-brilacidin-inhibits-sars-cov-2-covid-19-by-97-percent-in-a-human-lung-cell-line

Brilacidin Passed Safety Profile: Brilacidin has been tested through 4 Phase II Human Trials for 4 indications including a 500 patient Trial (Absssi Indication) thereby passing the safety hurdle for IND Designation

Brilacidin/Remdesivir Combination: In a test at the George Mason University RBL, the Lab combined Remdesivir with Brilacidin which resulted in a 99.85% Viral Load Reduction with insignificant traces of the virus remaining. http://www.ipharminc.com/press-release/2020/9/15/laboratory-testing-of-brilacidin-for-covid-19-in-combination-with-remdesivir-reduces-viral-load-by-nearly-100-percent

* FDA Pre-IND Meeting: Brilacidin http://www.ipharminc.com/press-release/2020/10/2/innovation-pharmaceuticals-announces-pre-ind-meeting-request-granted-by-fda-for-the-study-of-brilacidin-for-the-treatment-of-covid-19

You do realize...if "ASPIRE ate the rally"...IPIX has a bit more money in its coffer!

Good news today...once IND Designation approved...Emergency Use Authorization is available...

Maybe W.H. would be interested in pushing IND through Immediately for DJT's EUA????

...can always speculate!

PS. Wrong on $10M for trials...hint in PR...
"Numerous hospitals and provider networks domestically and abroad have expressed a strong interest in participating in the Brilacidin for COVID-19 clinical trial."

Trial sites abroad ... could be 25% of the cost domestically!

IMO...Leo has the $ banked for the full 120 patient trial!!!

You questions:

The answers are obvious...unreasonable expectations were being made by flippers and short players...to knock them down ...

IMO...we will have our answers ... and they will meet the RBL indicators.


1. exuberance premature? results from RBL testing supports rational exuberance...

2. "why hasn’t a deal been struck with big pharma as Leo is constantly leading us to believe that the company is in the process of having ongoing discussions with other parties?" Why wouldn't Big Pharma wait for Human Trials??? The Human trials are the empirical evidence and validation of the RBL test results indicators.

3. "If it is truly a 99.85% CV killer, why doesn’t the world know about it and why is B not being proclaimed as a miracle drug by the experts?" The Human trials are the empirical evidence and validation of the RBL test results indicators.

4. Why are we floundering at the penny level? OTC/pre-IND/FDA...watch when IND/FDA approval is issued.

5. Is the RATIONAL exuberance premature ...NO

6. "Should remain in check until human trials are concluded?"...IT IS!!!

Lemoncat...interesting comments:

Regarding: "Our little IPIX was never intended to get any major support for government and so it probably won't"...disagree with "probably won't" IMO Probably WILL based upon how high up Brialcidin is already known by Coronavirus Task Force chain and former Key Scientific Advisor's interest is in Brilacidin. IMO days after first dosing the reported commentary will be exciting.

Regarding: "hope we allocate some of that money to our B-IBD program which will have durability once the infectious disease hype is over." IMO Leo's experience will be reflected by not leaving any B-IBD opportunity and momentum dorment during the pursuant of B as a therapy for Covid-19.

Finally: IMO Leo will amaze investors just how far judicious management of available funds (not counting additional grant funds) can take IPIX up the FDA phased testing of both B-Covid-19 and B-IBD.

Consistent!...TOTALLY INCORRECT STATEMENT:

Leo does not have to sell any shares...he does not need capital for Brilacidin Human Trials for Covid-19...

AND... if and when Leo choses to raise capital (outside grant applications) he can do so up to $30 Million...BUT...HE chooses the price at which he "puts" the shares to the buyer...

SO...IPIX can choose if and when it wants to raise, and at what price.

Therefore....

IPIX can wait and raise all or part of the $30 Million when share prices reached $1 per share selling 30 million shares (NOT 100 Million Shares)...

or

wait and raise all or part of the $30 Million when share prices reached $3 per share selling 10 million shares (NOT 100 Million Shares)...

I believe we call that statement in your inaccurate post "pure deception by ... an exaggerator".

Interesting Consistently Negative and Inaccurate Commentary...while you also post that you have a very large BID (for a company and CEO you detest) at $.179

Leave conclusions for squaring your buying shares and trashing the company at the same time...NOT HARD TO FIGURE OUT!

PS Karin and Farrell and several others the boards super-stars! Investors would be well advises to listen to them closely.

1. It has the money for its planned Human Trials...it doesnt need to raise more...unless it chooses to.

2. Leo doesnt waste money...New Hire for Human Trials supervision speaks volumes as what the company is on the verge of...IMO no hire unless IND/FDA is imminent. Therefore IMO IPIX knows IND/FDA imminent.

3. List of regular IPIX disparages pointed out this AM...all using the same Canards...the straw-man is (NOT THAT BRILACIDIN IS NOT THE DYNAMIC THERAPUETIC ... the nation has been waiting for)... WHY WASN'T IT APPROVED YESTERDAY?

...Kobar...and others TAKE A DEEP BREATH...Dr Jeffery Howard, the recent former Key Scientific Advisor to V.P. Pence's Coronavirus Task Force...informed one of our MD. Posters here that upon a complete review of all what IPIX has done...IPIX (Leo) has done everything RIGHT...with bringing Brilacidin to FDA approval...and trials. (I saw and read his email). (third party Due Diligence...not from the company...and there is plenty more where that came from)

...sometimes ... especially in a highly partisan political FDA/CDC...you have to go stealth...not to become a target of being buried by deep state Actors within those agencies...These Health Officials (and some DR on this board) care more about not giving DJT any positive news before Nov 3rd, than the health of the nation.

The Science does not and will not lie...and it will not and cannot be refuted. Remdisivir is marginal without Brilacidin. Human trials (or compassionate use) will demonstrate that IMO within days of first dosing how incredibly effective Brilacidin will be and is.

I welcome more shares down here...I have my bid in.

ps. and Howard is the tip of the iceberg...regarding third party successful efforts by SH independently of the company.

VERY GOOD REASON WHY BRILACIDIN was not mentioned in NEW YORKER Article...

Article in these publications are summitted for Editorial Review at least 6 weeks before publication so they can be vetted for accuracy and verification of those quoted.

The New Yorker Article was PUBLISHED 09.18.2020

The article IMO was most likely submitted for Editorial Review on or before August 3rd.

IPIX appointed Dr. DeGrado as Scieintific Advisor on or about August 26th, 2020. (23 days before Publication of the New Yorker Article)

With Dr. DeGrado having conversation with IPIX before his appointment but not formalizing the relationship until on or about August 26th (Date of Announcement by IPIX)...the discussion of Brilacidin by Dr. DeGrado citing it in an Article to be published BEFORE the appointment would make the Citing of Brilacidin suspect (i.e. doing it to promote his financial interest?) and therefore inappropriate.

Therefore ... DeGrado did not cite it intentionally or if he did, the author/Editor chose not to report it.

REGARDING LEO'S EMAIL TO SHAREHOLDERS...The article not only validates the methodology of Dr. DeGrado's formulating Brilacidin to address bacterial and viral infections via De Nova designed drugs to mimic human proteins that serve as the front line of defense for the immune system...

IMO...we will shortly hear upon commencement of Human Trials (and superb success) that Brilacidin will be considered the first commercially available drug seeking FDA approval which was produced through this methodology...and it was done by DeGrado.

.

Re: New Yorker Article (Sept 20,2020) on De Novo Protein Design...to combat Covid-19


"Today, biochemists engineer proteins to fight infections..."  " But “de novo” protein design—design from scratch—has been “the holy grail of protein science for many decades,” Sarel Fleishman, a biochemist at the Weizmann Institute of Science, in Israel, told me. Designer proteins could help us cure diseases;   

In the nineteen-seventies, the pioneers of protein design worked by building physical models of their amino-acid chains. William DeGrado, a biochemist at the University of California, San Francisco, coined the term “de novo” protein design in the nineteen-eighties; he recalled, “I was told it was going to be impossible quite a bit.” 
"Protein design is a two-way street: you must figure out how to... (do) does something useful, such as binding, antibody-like, to a virus. (as in Brilacidin?) A protein designer might start by taking natural proteins and tweaking them. ..."

"...Thanks to improved computational tools, including Rosetta, and faster methods for making and testing proteins, de-novo design has begun to show real promise."

“It’s amazing how much progress has been made, and how it’s just accelerating so rapidly,” DeGrado said. Baker agreed that progress was speeding up. “The fact that we’re spinning out a couple of companies a year is kind of remarkable,” he said. His lab’s work on covid-19 has convinced him that the grail is almost within reach. “The hope is that the next time there’s an outbreak, within two days, we’ll have models of candidates,” he told me.  

IMO...DEGRADO DISCOVERED  THE "HOLY GRAIL" DECADES AGO...and as it applies to COVID-19 (and other viruses) ... it's called BRILACIDIN!

BooDog...smart!

Time to accumulate is not after significant news...but before. I'm with you all the way...quietly accumulating each day at dips appear...

4th Q is 7 days away...looking for significant news before...but...

IMO..IPIX will deliver (even more) then promised in 4th Q and will blow "the mind" of the collective market, by demonstrating in Human Trials how extremely very effective therapeutic for Covid-19 B is ...plus open the door to even more revelations concerning the brilliance of Brilacidin design for therapeutic applications for other indications...via Dr DeGrado.

...on my way to to 3M shares

There is no basis for assuming any positive information on IPIX successes with RBL's Test results etc...has hit "the market" yet.

If you referring to the OTC market...it worthless... IMO...as to "big picture, big pharma"...You can only judge when information hits "big market" and is brought to light with the regional/National Media...

right now...the SP fluctuation is indicative of a small, closed retail market of flippers...

Awareness and Recognition by Mainstream Media, BP or Federal Agency Announcements...then you can judge "market response"... to call it otherwise is simply setting up a straw-man to knock down as "a problem"...or suspect

Dissemination and recognition of the great successes IMO will come all together...and suddenly.

And...regardless of current IPIX SP recognition..."Those are some eye-popping raw numbers"!

DaubersUP

...you are absolutely correct! LEO has done everything "by the book" and through Third Party Due Diligence (outside the company)...I have been informed that a recently departed Scientific Advisor to the VP Task force (who remains close to the Task Force) has reviewed Brilacidin ,filings. RBL results and background of Brilacidin...and he noted to a MD/former researcher, who requested the review, that "IPIX has done everything the RIGHT WAY" (methodically and no hype or bs)...and, going forward, is very bullish on the mechanisms of Brilacidin against Covid-19.

... all the disparaging and misleading and at times flagerlantly false commentary posted on this board about LEO and Brilacidin is obvious to those who know Brilacidin and what they own.

How close are we to hearing Brilacidin on major cable channels?... you be the judge! IMO...Brilacidin is in the countdown period for lift-off.

Ignore the flippers...

Smith... you state ( on a day of monumentally good news) the following:

To directly respond to the statement which fails to address the stunning progress IPIX has made under LEO's The CEO, leadership and who started this quest with virtually no funds, or very little funding... my Third Party Sourced DD informs me he spoke with DR who until last month, was a key Administration Scientific Advisor on Covid-19 vaccines and therapies..(and still has significant ties and input) stated to him upon reviewed the actions and steps taken by IPIX in moving Brilacidin toward successful clinical trials that ..." the company has done everything the RIGHT WAY "... and would offer his services where necessary (if requested).

Wondering what the good Doctor has to say today...perhaps he is busy on the phone with the V.P.?

His statement to another Dr is a total renunciation of the substance of your post... and a warning to the shorts... "your days are numbered."

PS wondering how quickly Leo is going to receive a call from Gilead ? Brilacidin has put their cash cow Remdesivir to shame ... having only produced marginally statistical significant in reduction of alone.

"getting" ..."moving in the direction of"...many PRs cite doing so for Human Trials.

...if they "lost faith" it was well before Brilacidin...many more have gained faith in IPIX via Brilacidin...and rightfully so...




Would publications in the NYC and Metro LI be an adequate substitute?

...I thought so.

explain your accusations...

attracting DeGrado and bringing him into the process...a move worth millions